DAWN

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm headquartered in South San Francisco, California, dedicated to the development of targeted therapies for genetically defined cancers. The company's robust pipeline includes innovative treatments designed to meet significant unmet medical needs in oncology, emphasizing precision medicine that seeks to enhance patient outcomes by specifically targeting genetic mutations within tumors. By leveraging a strategic approach to drug development, Day One positions itself as a frontrunner in cancer therapeutics, showcasing its potential to revolutionize treatment paradigms and make a profound impact within the biopharmaceutical industry.